146 related articles for article (PubMed ID: 34711750)
1. Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study.
Masarone D; Melillo E; Errigo V; Martucci ML; Pacileo R; Pollesello P; Petraio A; Pacileo G
J Cardiovasc Pharmacol; 2022 Jan; 79(1):e36-e40. PubMed ID: 34711750
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience.
Masarone D; Valente F; Verrengia M; Ammendola E; Gravino R; D'Alterio G; Petraio A; Pacileo G
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):919-921. PubMed ID: 33017124
[No Abstract] [Full Text] [Related]
3. Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.
Najjar E; Stålhberg M; Hage C; Ottenblad E; Manouras A; Haugen Löfman I; Lund LH
ESC Heart Fail; 2018 Jun; 5(3):302-308. PubMed ID: 29469177
[TBL] [Abstract][Full Text] [Related]
4. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study.
García-González MJ; Jorge-Pérez P; Jiménez-Sosa A; Acea AB; Lacalzada Almeida JB; Ferrer Hita JJ
Cardiovasc Ther; 2015 Aug; 33(4):193-9. PubMed ID: 25959786
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
Ferreira Reis J; Valentim Gonçalves A; Ilhão Moreira R; Pereira da Silva T; Timóteo AT; Pombo D; Carvalho T; Correia C; Santos C; Cruz Ferreira R
Rev Port Cardiol; 2023 Apr; 42(4):335-343. PubMed ID: 36634758
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
Manito Lorite N; Rubio-Rodríguez D; González Costello J; Díez López C; Enjuanes Grau C; Segovia-Cubero J; Delgado Jimenez JF; Campo Sien C; Rubio-Terrés C; Comín-Colet J; ;
Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):361-367. PubMed ID: 31899185
[TBL] [Abstract][Full Text] [Related]
10. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
11. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial.
Altenberger J; Parissis JT; Costard-Jaeckle A; Winter A; Ebner C; Karavidas A; Sihorsch K; Avgeropoulou E; Weber T; Dimopoulos L; Ulmer H; Poelzl G
Eur J Heart Fail; 2014 Aug; 16(8):898-906. PubMed ID: 24920349
[TBL] [Abstract][Full Text] [Related]
13. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.
Tycińska A; Gierlotka M; Bartuś S; Gąsior M; Główczyńska R; Grześk G; Jaguszewski M; Kasprzak JD; Kubica J; Legutko J; Leszek P; Nessler J; Pacileo G; Ponikowski P; Sobkowicz B; Stępińska J; Straburzyńska-Migaj E; Wojakowski W; Zawiślak B; Zymliński R;
Adv Med Sci; 2022 Mar; 67(1):18-22. PubMed ID: 34656873
[TBL] [Abstract][Full Text] [Related]
14. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period.
Pölzl G; Allipour Birgani S; Comín-Colet J; Delgado JF; Fedele F; García-Gonzáles MJ; Gustafsson F; Masip J; Papp Z; Störk S; Ulmer H; Vrtovec B; Wikström G; Altenberger J
ESC Heart Fail; 2019 Feb; 6(1):174-181. PubMed ID: 30378288
[TBL] [Abstract][Full Text] [Related]
15. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function.
Capomolla S; Pozzoli M; Opasich C; Febo O; Riccardi G; Salvucci F; Maestri R; Sisti M; Cobelli F; Tavazzi L
Am Heart J; 1997 Dec; 134(6):1089-98. PubMed ID: 9424070
[TBL] [Abstract][Full Text] [Related]
16. [Effects of levosimendan on hemodynamics and cardiac function in patients with septic shock].
Fang M; Dong S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Oct; 26(10):692-6. PubMed ID: 25315937
[TBL] [Abstract][Full Text] [Related]
17. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study.
Dernellis J; Panaretou M
Chest; 2005 Oct; 128(4):2633-9. PubMed ID: 16236936
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients.
Ersoy O; Boysan E; Unal EU; Yay K; Yener U; Cicekcioglu F; Katircioglu F
Cardiovasc J Afr; 2013 Aug; 24(7):260-4. PubMed ID: 24217302
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial.
Burkhoff D; Borlaug BA; Shah SJ; Zolty R; Tedford RJ; Thenappan T; Zamanian RT; Mazurek JA; Rich JD; Simon MA; Chung ES; Raza F; Majure DT; Lewis GD; Preston IR; Rich S
JACC Heart Fail; 2021 May; 9(5):360-370. PubMed ID: 33839076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
